Identification of a prognostic long noncoding RNA signature in lung squamous cell carcinoma: a population-based study with a mean follow-up of 3.5 years.
LncRNAs
Lung squamous cell carcinoma
Survival
Journal
Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826
Informations de publication
Date de publication:
28 Apr 2021
28 Apr 2021
Historique:
received:
17
08
2020
accepted:
18
04
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Lung squamous cell carcinoma (LSCC) is a form of cancer that is associated with high rates of relapse, poor responsiveness to therapy, and a relatively poor prognosis. The relationship between long non-coding RNA (lncRNA) expression and LSCC patient prognosis remains to be established. In the present study, we discovered that lncRNAs were differentially expressed in LSCC tumor tissues relative to normal control tissues, and we explored the prognostic relevance of these lncRNA expression patterns using data from the Cancer Genome Atlas (TCGA). These multidimensional data were analyzed in order to identify lncRNA signatures that were associated with LSCC patient survival outcomes. Kaplan-Meier survival curves revealed prognostic capabilities for three of these lncRNAs (LINC02555, APCDD1L-DT and OTX2-AS1). A Cox regression analysis revealed this three-lncRNA signature to be significantly associated with patient survival. Further GO and KEGG analyses revealed that the predicted target genes of these three lncRNAs were also potentially involved in cancer-associated pathways. Together these results thus indicate that this novel three-lncRNA signature can be used to predict LSCC patient prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Lung squamous cell carcinoma (LSCC) is a form of cancer that is associated with high rates of relapse, poor responsiveness to therapy, and a relatively poor prognosis. The relationship between long non-coding RNA (lncRNA) expression and LSCC patient prognosis remains to be established.
METHODS
METHODS
In the present study, we discovered that lncRNAs were differentially expressed in LSCC tumor tissues relative to normal control tissues, and we explored the prognostic relevance of these lncRNA expression patterns using data from the Cancer Genome Atlas (TCGA).
RESULTS
RESULTS
These multidimensional data were analyzed in order to identify lncRNA signatures that were associated with LSCC patient survival outcomes. Kaplan-Meier survival curves revealed prognostic capabilities for three of these lncRNAs (LINC02555, APCDD1L-DT and OTX2-AS1). A Cox regression analysis revealed this three-lncRNA signature to be significantly associated with patient survival. Further GO and KEGG analyses revealed that the predicted target genes of these three lncRNAs were also potentially involved in cancer-associated pathways.
CONCLUSIONS
CONCLUSIONS
Together these results thus indicate that this novel three-lncRNA signature can be used to predict LSCC patient prognosis.
Identifiants
pubmed: 33910626
doi: 10.1186/s13690-021-00588-2
pii: 10.1186/s13690-021-00588-2
pmc: PMC8082628
doi:
Types de publication
Journal Article
Langues
eng
Pagination
61Références
DNA Cell Biol. 2020 Mar;39(3):459-473
pubmed: 31934791
Biomed Pharmacother. 2019 Jan;109:1851-1859
pubmed: 30551440
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
J Cell Biochem. 2019 Dec;120(12):19415-19421
pubmed: 31448453
Cell Mol Life Sci. 2019 Jun;76(11):2059-2076
pubmed: 30683984
Int Rev Cell Mol Biol. 2016;326:33-65
pubmed: 27572126
Oncol Lett. 2017 May;13(5):3494-3500
pubmed: 28529576
Biochim Biophys Acta. 2015 Dec;1856(2):189-210
pubmed: 26297204
J Cell Physiol. 2018 Sep;233(9):6689-6704
pubmed: 29215699
J Cell Biochem. 2018 Nov;119(11):9072-9080
pubmed: 30010215
Med Sci Monit. 2018 Feb 05;24:718-726
pubmed: 29398692
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Exp Ther Med. 2018 Dec;16(6):4991-5002
pubmed: 30542454
Nat Rev Genet. 2014 Jun;15(6):423-37
pubmed: 24776770
Cancer Manag Res. 2018 May 30;10:1377-1387
pubmed: 29881308
Clin Chim Acta. 2019 Dec;499:75-80
pubmed: 31476304
Tob Control. 2008 Jun;17(3):198-204
pubmed: 18390646
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Lung Cancer. 2019 Sep;135:21-28
pubmed: 31446997
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Biochem Biophys Res Commun. 2019 Feb 26;510(1):171-176
pubmed: 30670309
Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
pubmed: 11790668
Virus Res. 2016 Jan 2;212:137-45
pubmed: 26362525
Cell. 2015 Jan 29;160(3):489-502
pubmed: 25619690
Cancer Cell Int. 2018 Jul 4;18:91
pubmed: 29997452
Cell Signal. 2015 Mar;27(3):403-15
pubmed: 25530216
J Am Acad Dermatol. 2014 Oct;71(4):611.e1-611.e10; quiz 621-2
pubmed: 25219717
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741